Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Assenagon Asset Management S.A. cut its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 71.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,937 shares of the company's stock after selling 158,767 shares during the quarter. Assenagon Asset Management S.A. owned about 0.16% of Keros Therapeutics worth $1,028,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KROS. Geode Capital Management LLC raised its stake in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after purchasing an additional 46,041 shares in the last quarter. Barclays PLC raised its position in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Keros Therapeutics in the third quarter valued at approximately $868,000. Point72 DIFC Ltd grew its position in Keros Therapeutics by 9.8% during the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company's stock worth $1,118,000 after buying an additional 1,715 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after acquiring an additional 577,220 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded down $0.18 during midday trading on Friday, reaching $11.84. The company had a trading volume of 1,494,908 shares, compared to its average volume of 1,908,576. The stock has a fifty day moving average price of $31.26 and a 200 day moving average price of $46.06. Keros Therapeutics, Inc. has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The firm has a market cap of $479.64 million, a PE ratio of -2.27 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the business earned ($1.33) EPS. The business's revenue for the quarter was up 4750.0% on a year-over-year basis. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Wedbush lowered shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. TD Cowen downgraded shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Finally, HC Wainwright reduced their target price on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $52.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.